Bin Tian appointed professor, co-director of the Center for Systems & Computational Biology at Wistar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bin Tian was appointed professor at the The Wistar Institute Cancer Center.

A molecular biologist by training, Tian focuses on RNA biology and understanding how gene expression is regulated at the post-transcriptional level. His research involves interdisciplinary approaches, including molecular biology, genomics and computational biology, to study RNA biogenesis and metabolism. His lab was among the first to characterize the functional genomics of alternative polyadenylation and has uncovered its role in many diverse cellular processes.

“Bin’s research has led to groundbreaking advances understanding the role of alternative polyadenylation in development and cell differentiation as well as in the context of cancer and cellular stress,” Dario C. Altieri, Wistar president and CEO, director of the Cancer Center, and the Robert and Penny Fox Distinguished Professor, said in a statement. “Bin’s work strengthens our RNA biology research and brings expertise in complex computational and genomic methods that will synergize with the work of our scientists across our research programs.”

Tian joins Wistar from Rutgers New Jersey Medical School, where he was a professor. In 2003, he established his research group at Rutgers New Jersey Medical School where he became a tenured professor in 2014.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login